- Home
- BBDO vs NTRA Comparison
BBDO vs NTRA Comparison
Compare BBDO & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBDO
- NTRA
- Stock Information
- Founded
- BBDO 1943
- NTRA 2003
- Country
- BBDO Brazil
- NTRA United States
- Employees
- BBDO N/A
- NTRA N/A
- Industry
- BBDO Major Banks
- NTRA Medical Specialities
- Sector
- BBDO Finance
- NTRA Health Care
- Exchange
- BBDO Nasdaq
- NTRA Nasdaq
- Market Cap
- BBDO N/A
- NTRA 20.9B
- IPO Year
- BBDO N/A
- NTRA 2015
- Fundamental
- Price
- BBDO $2.40
- NTRA $162.57
- Analyst Decision
- BBDO Strong Buy
- NTRA Strong Buy
- Analyst Count
- BBDO 3
- NTRA 17
- Target Price
- BBDO $2.55
- NTRA $176.65
- AVG Volume (30 Days)
- BBDO 81.0K
- NTRA 1.1M
- Earning Date
- BBDO 05-08-2025
- NTRA 05-08-2025
- Dividend Yield
- BBDO 5.70%
- NTRA N/A
- EPS Growth
- BBDO 46.25
- NTRA N/A
- EPS
- BBDO 0.31
- NTRA N/A
- Revenue
- BBDO $14,594,673,370.00
- NTRA $1,696,911,000.00
- Revenue This Year
- BBDO $68.70
- NTRA $15.45
- Revenue Next Year
- BBDO $8.99
- NTRA $18.43
- P/E Ratio
- BBDO $7.00
- NTRA N/A
- Revenue Growth
- BBDO 23.24
- NTRA 56.75
- 52 Week Low
- BBDO $1.71
- NTRA $92.14
- 52 Week High
- BBDO $2.64
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- BBDO 67.24
- NTRA 62.32
- Support Level
- BBDO $2.10
- NTRA $153.40
- Resistance Level
- BBDO $2.02
- NTRA $159.15
- Average True Range (ATR)
- BBDO 0.07
- NTRA 5.49
- MACD
- BBDO 0.01
- NTRA 1.30
- Stochastic Oscillator
- BBDO 88.89
- NTRA 94.64
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.